- Home
- GXAI vs GRDX Comparison
GXAI vs GRDX Comparison
Compare GXAI & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | GRDX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GXAI | GRDX |
|---|---|---|
| Price | $1.57 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.0M | 136.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,027.00 | N/A |
| Revenue This Year | $42,959.35 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1473.05 | N/A |
| 52 Week Low | $1.00 | $1.92 |
| 52 Week High | $2.96 | $5.30 |
Technical Indicators
Market Signals| Indicator | GXAI | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 37.63 |
| Support Level | $1.53 | $2.03 |
| Resistance Level | $1.70 | $3.65 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 35.77 | 11.70 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About GRDX GridAI Technologies Corp.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.